Xylem and Partners Volunteer 157,000 Hours Toward Solving Water and Sustainability Challenges in 2022
20.2.2023 17:00:00 EET | Business Wire | Press release
Global water technology leader, Xylem (NYSE: XYL), reports that 87% of employees volunteered time in 2022, combining their efforts with volunteers from Xylem’s customers and partners around the world. The employee volunteers dedicated 157,000 hours during the year, an increase of 39% from 2021.
More than 15,600 employees participated in Xylem’s corporate social responsibility program, Xylem Watermark, in 2022, supporting a range of initiatives such as educating the next generation about critical water challenges, expanding access to safe water and sanitation, and supporting communities in crisis.
“Xylem Watermark is fundamental to our mission to solve the world’s biggest water challenges,” said Austin Alexander, Vice President of Sustainability and Social Impact at Xylem. “Our employees and partners showed remarkable commitment to solving short- and long-term water challenges in 2022, with 160 offices having 100% employee participation. We are proud of our teams and partners, who have already begun 2023 by volunteering in response to community needs, everywhere, including support for relief efforts and provision of fresh water to earthquake-affected regions of Turkey.”
“In 2022, our partnership with Xylem delivered clean water and sanitation to more than 2 million people affected by poverty or disaster,” said Rose Hogan, Interim Technical Unit Vice President at Americares. “Through the continued commitment of the Xylem team, we’ve provided water, sanitation, and hygiene education in India and Bangladesh, including infrastructure improvements and critical repairs in 27 health centers and six schools. We are incredibly proud of what we’ve achieved together in 2022.”
Employee’s volunteer efforts also contribute to Xylem’s 2025 Sustainability Goals, which include: providing access to clean water and sanitation for at least 20 million people; providing water and WASH (Water and Sanitation Hygiene) education for 15 million people; and giving 1% of profits and 1% of employee time to water-related causes and education.
In 2022, Xylem Watermark projects included:
- To support relief efforts in Ukraine, Xylem employees raised funds, hosted refugee families, collected supplies, donated equipment, and deployed emergency water treatment systems that serve 128,000 people.
- Xylem’s Humanitarian Disaster Response Team provided emergency water treatment systems in Ukraine, South Africa, Pakistan, and the Philippines.
- Employees raised water scarcity awareness and reduced water pollution through the global “Take Steps to Solve Water” campaign, featuring Manchester City manager Pep Guardiola.
- Partnering with NGO organizations including Americares, Engineers Without Borders, and Planet Water Foundation, Xylem Watermark supported the expansion of safe water and sanitation access to schools, hospitals, and communities, reaching 2.4 million people.
- Xylem Ignite continued to inspire future water leaders, with more than 1,200 students participating in the second annual Global Student Innovation Challenge and the Re-New Our World Challenge in the Middle East.
About Xylem
Xylem (XYL) is a leading global water technology company committed to solving critical water and infrastructure challenges with innovation. Our more than 17,000 diverse employees delivered revenue of $5.5 billion in 2022. We are creating a more sustainable world by enabling our customers to optimize water and resource management, and helping communities in more than 150 countries become water-secure. Join us at www.xylem.com.
About Xylem Watermark
Xylem Watermark, the Company’s corporate citizenship program, was initiated in 2008, with a focus on protecting and providing safe water resources around the world and also educating people on water-related issues. The global initiative, which encompasses employee and stakeholder engagement, provides access to clean drinking water and sanitation, and humanitarian emergency response to help communities become more water-secure and sustainable.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230220005154/en/
Contact information
Houston Spencer
+1 (914) 240-3046
Houston.Spencer@xylem.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
